MedPacto, Inc.
Financials
Valuation Metrics
MedPacto, Inc.'s Market Cap is ₩951B. At end of 2025 it was ₩2290B. Ranked #1312 of 2,421 in KR market (top 54%), #725 of 1,640 on KOSDAQ (top 44%), #145 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 63%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 95.11B KRW | KR#1,312/2,421 Sec#145/231 |
| Revenue | 4.99B KRW | KR#2,343/2,421 Sec#196/231 |
| Net Income | -14.14B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 48.66B KRW | KR#2,221/2,421 Sec#204/231 |
| Net Assets | 45.98B KRW | KR#1,963/2,421 Sec#167/231 |
| Employees | 57 | KR#1,989/2,421 Sec#177/231 |
| Value | ||
| P/B | 2.07x | KR#1,956/2,421 Sec#144/231 |
| P/S | 19.04x | KR#2,334/2,421 Sec#184/231 |
| FCF Yield | -14.17% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -30.75% | KR#2,190/2,421 Sec#177/231 |
| ROA | -29.06% | KR#2,313/2,421 Sec#201/231 |
| Op. Margin | -309.63% | KR#2,350/2,421 Sec#195/231 |
| Revenue Growth | 293.41% | KR#21/2,421 Sec#7/231 |
| Financial Health | ||
| Debt Ratio | 5.83% | KR#45/2,421 Sec#13/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -13.48B KRW | KR#1,795/2,421 Sec#162/231 |
| Cash | 12.00B KRW | KR#1,582/2,421 Sec#133/231 |
| Current Ratio | 23.06x | KR#20/2,421 Sec#8/231 |
| Performance | ||
| 1Y Return | -40.51% | KR#1,843/2,421 Sec#155/231 |
| 1M Return | 13.96% | KR#359/2,421 Sec#20/231 |
| From 52W High | -67.92% | KR#2,141/2,421 Sec#179/231 |
| 1Y MDD | -72.17% | KR#2,076/2,421 Sec#181/231 |
| Trading | ||
| Volume | 175,167 shares | KR#529/2,421 Sec#36/231 |
| Trading Value | 491.9M KRW | KR#928/2,421 Sec#94/231 |
| Foreign Own. | 4.42% | KR#964/2,421 Sec#84/231 |
| Per Share | ||
| EPS | -413 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,342 KRW | KR#2,231/2,421 Sec#198/231 |
Company Info
The company, a bio company that spun off from Theragen Etex in 2013, was listed on the KOSDAQ market in 2019 as a technology growth company. It develops innovative new drugs for treating intractable cancer and chronic diseases, and discovers new drug candidate targets using advanced genome analysis technologies like next-generation sequencing and bioinformatics. Its flagship Baektoseoptip is under co-development for combination therapy with MSD and AstraZeneca. The company pursues precision medicine innovation with customized therapeutics and MA-B2 target antibody therapeutics. MedPacto, established in 2013, is headquartered in Seocho District, Seoul Metropolitan City.